Omeros, a clinical stage biopharmaceutical company, has announced that has submitted a new drug application to the FDA for its OMS302, a drug for use during intraocular lens replacement surgery.
Omeros also intends to submit a marketing authorization application to the European Medicines Agency.
More Articles on Ophthalmology:
Global Surgical Ophthalmology Market to be Worth $9B by 2017
Valeant to Reduce Workforce by 15% After Bausch +Lomb Buyout
7 Recent Ophthalmologist Moves